Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.75 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CCKBR | P32239 | 1/20 | 0.64 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teduglutide SCHEMBL29358495 | 0.99 | GLP1R (0.74) | GLP1RCRHR1CRHR2CCKBRPTH1R | |
| SCHEMBL29385782 | 0.94 | GLP1R (0.73) | GLP1RCCKBRPTH1R | |
| SCHEMBL29599165 | 0.93 | GLP1R (0.65) | GLP1RCCKBRPTH1R | |
| SCHEMBL29599744 | 0.93 | GLP1R (0.66) | GLP1RCRHR1CRHR2CCKBRPTH1R | |
| Teduglutide SCHEMBL29393085 | 0.93 | GLP1R (0.73) | GLP1RCCKBRPTH1R | |
| SCHEMBL29462208 | 0.92 | GLP1R (0.74) | GLP1RCRHR1CRHR2CCKBR | |
| SCHEMBL29373831 | 0.92 | GLP1R (0.77) | GLP1R | |
| SCHEMBL30657454 | 0.92 | GLP1R (0.75) | GLP1RCCKBRPTH1R | |
| SCHEMBL30358210 | 0.92 | GLP1R (0.74) | GLP1RCCKBR | |
| SCHEMBL30518506 | 0.92 | GLP1R (0.74) | GLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-3689898-B1 | LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| EP-4727595-A2 | HEPATOCYTE TARGETING MOLECULES AND METHODS OF USE THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260035429-A1 | METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES | YUHAN CORPORATION (KR) | 2026-02-05 | — | — | US | claimed |
| EP-4654986-A1 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND THEIR MEDICAL USES FOR THE TREATMENT OF SHORT BOWEL SYNDROME (SBS) | Zealand Pharma A/S (DK) | 2025-12-03 | — | — | EP | claimed |
| US-20250332099-A1 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA AS (DK) | 2025-10-30 | — | — | US | claimed |
| EP-4640234-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GRAFT-VERSUS-HOST DISEASE CONTAINING GLP-2 DERIVATIVE OR LONG-ACTING CONJUGATE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-10-29 | — | — | EP | claimed |
| EP-4398872-B1 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA AS (DK) | 2025-10-22 | — | — | EP | claimed |
| EP-4627351-A1 | METHODS FOR DETECTING METABOLIC MARKERS | Cedars-Sinai Medical Center (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4619423-A1 | DUAL FUNCTION PROTEINS AND USES THEREOF | Yuhan Corporation (KR) | 2025-09-24 | — | — | EP | claimed |
| US-20220251164-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-11401305-B2 | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | XL-PROTEIN GMBH (DE) | 2022-08-02 | — | — | US | claimed |
| US-11384123-B2 | Mucoadhesive microorganism | INTREXON ACTOBIOTICS N.V. (BE) | 2022-07-12 | — | — | US | claimed |
| EP-4013395-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | Applied Molecular Transport Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| CN-114555058-A | Compositions and particles for payload delivery | 应用分子转运公司 | 2022-05-27 | — | — | CN | claimed |
| EP-3999531-A1 | METALLOTHIONEIN ANTIBODIES AND THEIR USE | University of Connecticut (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-11267863-B2 | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same | PEPGENE INC. (KR) | 2022-03-08 | — | — | US | claimed |
| CN-114127105-A | Anti-metallothionein antibodies and uses thereof | 康涅狄格大学 | 2022-03-01 | — | — | CN | claimed |
| US-20220031810-A1 | FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA A/S (DK) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035429-A1 | METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES | GIPR, FGF23, BMPR2 | GLP1R 48/4885CRHR1 167/4885CRHR2 120/4885 |
| US-20220251164-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | GLP1R, GIPR, IAPP | GLP1R 1/4885CRHR1 306/4885CRHR2 76/4885 |
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | GLP1R 671/4885CRHR1 1608/4885CRHR2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.